Moderna, Inc. Common Stock (MRNA)
Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.
Company News
CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.
Moderna discontinued its cytomegalovirus (CMV) vaccine program after a Phase 3 trial failed to meet primary efficacy endpoints in preventing infection among women aged 16-40. The vaccine showed only 6-23% efficacy, well below the company's target.
Despite recent financial challenges, Moderna is positioned for potential growth through its innovative mRNA platform and promising cancer vaccine candidate mRNA-4157, which shows significant potential in clinical trials across multiple cancer types.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
